Inovio INO-5401 + INO-9012 with Libtayo combo shows potential treatment for glioblastoma

 

• Inovio (NASDAQ:INO) announces that data from its novel combination trial of DNA medicines INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), will be presented at the Society for Neuro-Oncology 2020 Annual Meeting.
• The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival.
• Survival data at 18 months showed that 70% (14/20) of MGMT promoter methylated GBM patients were alive, and 50% (16/32) of MGMT promoter unmethylated patients, which are the more difficult to treat group, were alive.
• Median overall survival (OS) in the unmethylated GBM patients was 17.9 months, which compares favorably to historical controls; Median OS for methylated patients has not yet been reached and the study is ongoing.
• In the unmethylated cohort, 19/22 (86%) subjects and in methylated cohort, 19/22 (86%) subjects had an IFN-gamma T cell response that increased over baseline to one or more of the antigens encoded by INO-5401.
• The combination demonstrated well-tolerated safety profile when given not only with radiation and TMZ, but also with Libtayo, which is being jointly developed by Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY).
• Additional data will be provided in the coming months.
• https://seekingalpha.com/news/3638311-inovios-inominus-5401-inominus-9012-libtayo-combo-shows-potential-treatment-for-glioblastoma